IXIARO

Compare IXIARO  to:
Compare
Compare

Generic Name for IXIARO

Japanese encephalitis virus vaccine; inactivated; aluminum hydroxide adsorbed; susp for IM inj; contains formaldehyde, protamine sulfate; preservative-free.

Legal Classification:

Rx

Pharmacological Class for IXIARO

Japanese encephalitis vaccine.

Manufacturer of IXIARO

Novartis Pharmaceuticals Corp

Indications for IXIARO

Japanese encephalitis immunization.

Adult dose for IXIARO

≥17yrs: Two doses given 28 days apart. Each dose is 0.5mL IM into deltoid muscle; complete series at least 1 week prior to potential exposure.

Children's dosing for IXIARO

<17yrs: not recommended.

Contraindications for IXIARO

Severe allergic reaction (eg, anaphylaxis) after a previous dose.

Precautions for IXIARO

Immunodeficiency. Bleeding disorders. Acute febrile illness. Allergy to protamine sulfate. Have epinephrine inj (1:1000) available. Pregnancy (Cat.B). Nursing mothers.

Interactions for IXIARO

Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.

Adverse Reactions for IXIARO

Local reactions (eg, pain, tenderness), headache, myalgia, fatigue, flu-like illness, GI upset, pyrexia.

How is IXIARO supplied?

Single-dose syringe (0.5mL)—1

Related Disease:

Immunization

Related Resources

Prevnar 13 pneumococcal disease vaccine approved

February 24, 2010

The FDA has approved Wyeth's Prevnar 13 (pneumococcal 13-valent conjugate vaccine) for the prevention of invasive pneumococcal disease and otitis media in children 6 weeks through 5 years of age.

Menveo vaccine approved for meningococcal disease immunization

February 22, 2010

Novartis announced that the FDA has approved Menveo (meningococcal [Groups A, C, Y, W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for the active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11-55 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA update on H1N1 vaccine safety monitoring

January 19, 2010

The Commissioner of Food and Drugs has issued a letter to update healthcare professionals on the FDA/CDC experience with the H1N1 vaccination program and to provide some detail on the current vaccine safety monitoring program.

Fluzone High-Dose influenza vaccine approved for adults ages 65 and older

December 28, 2009

Fluzone High-Dose (inactivated influenza virus vaccine, from Sanofi Pasteur) has been approved for use in adults ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.